-+ 0.00%
-+ 0.00%
-+ 0.00%

EUROPEAN COMMISSION GRANTS MARKETING AUTHORISATION FOR NEZGLYAL® (LERIGLITAZONE), THE FIRST PHARMACOLOGICAL TREATMENT APPROVED FOR CEREBRAL ADRENOLEUKODYSTROPHY (CALD), A RARE NEURODEGENERATIVE DISEASE

Reuters·09/25/2026 07:00:14

Please log in to view news